**Core tip:** Isolated adrenal metastasis from endometrial cancer is uncommon but should be suspected in patients with history of gynecological cancer. We report a case of large, metachronous adrenal metastasis from endometrial cancer successfully treated with laparoscopic resection. Mini-invasive surgery is safe and feasible with good oncological results also for metastatic lesions of adrenal gland.

INTRODUCTION
============

Secondary tumors are the second most common cause of adrenal cortex neoplasms, and carcinoma (especially in the advanced stage) accounts for more than 90% of secondary tumors\[[@B1]\]. In order of frequency, the most common primary sites of the metastatic carcinoma are: Lung cancer, breast cancer, and gastrointestinal cancers, followed by malignant melanoma and thyroid neoplasms. The metastatic involvement of adrenal glands by endometrial carcinoma is rare, and there is some controversy over the most appropriate treatment due to the lack of specific guidelines. The prognosis for patients with secondary tumors involving the adrenal glands is generally poor, but survival rates seem to improve in some cases after surgical resection. The National Comprehensive Cancer Network (NCCN) guidelines on malignancies of the adrenal glands recommend a direct open approach, while laparoscopic adrenalectomy is the gold standard in Europe, and the open approach is reserved for masses more than 6-8 cm in diameter, cases of extra-adrenal tissue invasion, or patients with contraindications to laparoscopy\[[@B2],[@B3]\].

We present an unusual case of metachronous uterine cancer metastasizing to an adrenal gland that was successfully treated with laparoscopic resection. A review of cases previously reported in the English literature was undertaken to ascertain what is currently known about the treatment of this unusual condition. A comprehensive search was run in PubMed (Medline) and Scopus as at December 2018 using the keywords: "adrenal gland neoplasms", adrenal metastasis", "uterine cancer", "endometrial cancer". The "related articles" function was used to widen the search and all abstracts, studies, and citations retrieved were reviewed.

CASE PRESENTATION
=================

Chief complaints
----------------

A 53-year-old Caucasian woman was admitted in November 2017 for an adrenal mass.

History of present illness
--------------------------

In 2014 she had undergone total hysterectomy, bilateral oophorectomy and pelvic lymphadenectomy for a grade 2, International Federation of Gynecology and Obstetrics (FIGO) stage III A endometrioid endometrial cancer (EEC). Postoperatively, she was treated with six cycles of carboplatin-paclitaxel chemotherapy. She had no known family history of colon cancer, and endometrial cancer related to Lynch syndrome was ruled out.

History of past illness
-----------------------

The patient had a history of laparoscopic uterine myomectomy and tonsillectomy when she was younger.

Physical examination
--------------------

Physical examination revealed abdominal tenderness with moderate palpation of the left mid-quadrant of the abdomen.

Imaging examinations
--------------------

Computed tomography (CT) of the chest and abdomen revealed a solid left adrenal mass with malignant features (6 cm in diameter, with parenchymal invasion) (Figure [1](#F1){ref-type="fig"}).

![Computed tomography scan of abdomen showing left adrenal mass measuring 40 mm × 34 mm.](WJCC-7-1844-g001){#F1}

Laboratory examinations
-----------------------

Laboratory test findings, including hormonal assays, were unremarkable.

FINAL DIAGNOSIS
===============

Macroscopic examination of the resected specimen showed the left adrenal gland (7 × 4 × 3 cm) almost entirely substituted by a solid, off-white neoplastic mass (6.8 cm in largest diameter). Microscopic sections showed massive adrenal and peri-adrenal endometrioid metastasis (Figure [2](#F2){ref-type="fig"}). Immunohistochemical staining was positive for progesterone and estrogen receptors (Figure [3](#F3){ref-type="fig"}).

![Hematoxylin and eosin stain of endometrial endometrioid carcinoma. A: Panoramic view of left adrenal gland; B: High magnification showing the glandular pattern of neoplastic cells.](WJCC-7-1844-g002){#F2}

![Immunohistochemical staining. A, B: Immunohistochemical staining positive for estrogen receptors (A) And progesterone receptors (B) Shows high reactivity in metastatic cells.](WJCC-7-1844-g003){#F3}

TREATMENT
=========

Laparoscopic adrenalectomy was performed.

OUTCOME AND FOLLOW-UP
=====================

The postoperative course was uneventful and the patient was discharged 5 d after the surgical procedure. Two months later, 18-FDG positron emission tomography showed no pathological uptake, so no adjuvant therapy was administered. At the latest follow-up (December 2018), the patient was in good clinical condition with no recurrent disease.

DISCUSSION
==========

Endometrial cancer is the most common gynecological cancer in developed countries. Most endometrial cancers are diagnosed at an early FIGO stage, and the most common histological type is EEC. These patients are generally considered at low risk, with 5-year survival rates of 95%; however, survival drop considerably to 69% and 13%, respectively, in the event of regional or distant metastases. Patients with endometrioid cancer in FIGO stages II to III, or with non-endometrioid cancer are at high risk of relapse\[[@B4]\]. The adrenal gland is a rare site of metastases from endometrial cancer. To our knowledge, only 11 previous cases have been reported in the English literature (Table [1](#T1){ref-type="table"}), including: 8 cases of metachronous single-site metastases, 2 of metachronous multiple-site metastases, and one synchronous metastasis. Nakano et al\[[@B5]\] were the first to report a case of adrenal metastasis from endometrial cancer in 1975. On reviewing all the studies listed in Table [1](#T1){ref-type="table"}: The patients' median age was 62 years (range 39-77 years). There were two patients with FIGO stage I disease, two with FIGO stage II, two with FIGO stage III, and two with FIGO stage IV, while the stage was not stated in three cases. Six patients had an endometrioid histology, four had a non-endometrioid type, and no histology was available for one. When stratified according to the European Society of Medical Oncology 2016 Consensus Conference recommendations, nine patients were at high risk of recurrence or distant meta-stases\[[@B4]\].

###### 

Patients with adrenal metastases from endometrial cancer

  **Case reports**                     **Age (yr)**   **Histology of primary**          **Stage (FIGO)**   **Adjuvant treatment**                           **DFS (mo)**   **Site**                      **Treatment**                                                                                              **F-U (mo)**
  ------------------------------------ -------------- --------------------------------- ------------------ ------------------------------------------------ -------------- ----------------------------- ---------------------------------------------------------------------------------------------------------- --------------
  Nakano et al\[[@B5]\], 1975          77             Mixed                             Na                 Na                                               26             Metachronous multiple sites   Whole brain irradiation and supportive care                                                                28
  (clear cell-squamous)                                                                                                                                                                                                                                                                                             
  Lam et al\[[@B6]\], 2001             Na             Na                                Na                 Na                                               Na             Metachronous single site      Laparotomic adrenalectomy                                                                                  Na
  Baron et al\[[@B7]\], 2008           76             Endometrioid G1                   IV B               EBRT                                             9              Metachronous single site      Laparotomic partial adrenalectomy                                                                          24
  Baron et al\[[@B7]\], 2008           62             Endometrioid G1                   Na                 VBT + 6 adriamycin- cisplatin cycles             108            Metachronous multiple site    Supportive treatment                                                                                       110
  Izaki et al\[[@B8]\], 2010           55             Endometrioid                      III C              7 carboplatin paclitaxel cycles                  15             Metachronous single site      Laparoscopic adrenalectomy + CT (3 carboplatin cycles)                                                     82
  Choi et al\[[@B9]\], 2011            62             Squamous                          III C              6 cisplatin cycles                               10             Metachronous single site      Laparoscopic adrenalectomy                                                                                 45
  Berretta et al\[[@B10]\], 2013       67             Mixed (anaplastic-endometrioid)   IV B               Na                                               Na             Synchronous multiple sites    One-time laparotomic adrenalectomy + hysterectomy and salpingectomy + taxol and carboplatin chemotherapy   Na
  Zaidi et al\[[@B11]\], 2013          75             Endometrioid G3                   I B                Na                                               6              Metachronous single site      Supportive treatment                                                                                       9
  Singh Lubana et al\[[@B12]\], 2015   60             Serous                            II                 EBRT + C + CT: 3 paclitaxel carboplatin cycles   66             Metachronous single sites     Laparotomic                                                                                                90
  adrenalectomy                                                                                                                                                                                                                                                                                                     
  Rekhi et al\[[@B13]\], 2015          39             Endometrioid G2                   II                 VBT + EBRT                                       24             Metachronous single site      Robotic adrenalectomy + CT                                                                                 Na
  Mouka et al\[[@B14]\], 2016          58             Endometrioid G3                   I B                6 CT                                             12             Metachronous single site      Laparotomic                                                                                                Na
  adrenalectomy + CT                                                                                                                                                                                                                                                                                                
  Present case, 2019                   53             Endometrioid G2                   II B               No treatment                                     36             Metachronous single site      Laparoscopic adrenalectomy                                                                                 45

FIGO: International Federation of Gynecology and Obstetrics; DFS: Disease-free survival; F-U: Follow-up; Na: Not available; EBRT: External beam radiation therapy; VBT: Vaginal brachytherapy; CT: Chermotherapy.

In most cases, the adrenal lesions were identified on CT scans. Laboratory tests revealed no hormone overproduction in any of the patients.

Gynecological and oncological societies have no shared approach to the adjuvant treatment of "high-risk" endometrial cancer. While the value of external beam radiotherapy and/or vaginal brachytherapy for local recurrence control is accepted almost worldwide, any use of chemotherapy to prevent distant relapses is at the clinician's discretion\[[@B15]\]. Our review identified seven cases treated with adjuvant therapy after gynecological surgery: 4 patients were administered radiotherapy at least; 3 were treated with chemotherapy alone.

Disease-free survival after hysterectomy naturally varied considerably, given the marked differences between the cases reviewed in terms of disease stage and grade, histology, and adjuvant therapy. It ranged from 6 mo to 108 mo with a median disease-free survival in the series of 15 mo.

The surgical approach to adrenal gland metastases is controversial. Following the NCCN guidelines, many authors treat adrenal metastases directly with open surgery\[[@B16]\], but laparoscopic adrenalectomy has been used successfully for a variety of secondary tumors\[[@B17],[@B18]\].

Our review found that only three of eight cases of single-site adrenal metastases from endometrial cancer (5.7-7.5 cm in diameter) were treated mini-invasively (laparoscopy or robotic surgery). The largest tumor (7.5 cm in diameter) was treated by Rekhi et al\[[@B13]\] with robotic adrenalectomy. Five patients underwent open adrenalectomy, and the largest tumor was reportedly 5 cm in diameter (range 3.5-5 cm). Our patient was successfully treated using a laparoscopic approach with no operative complications and with a good survival. A good outcome after mini-invasive surgery was reported by other Authors too. Izaki et al\[[@B8]\] and Choi et al\[[@B9]\] reported two similar cases, both high-risk patients with FIGO stage IIIC primary endometrial cancer and metachronous single-site adrenal metastases (5.7 and 6.0 cm in diameter, respectively); both patients were treated laparoscopically and had a long follow-up (82 and 45 mo, respectively).

So, despite the small number of patients considered, our review suggests that a laparoscopic approach is a valid alternative to open surgery for isolated adrenal metastases from endometrial cancer.

Finally, there is no general consensus regarding chemo-therapy after surgery for adrenal metastases. Izaki et al\[[@B8]\] described a patient who underwent laparoscopic adrenalectomy followed by three cycles of carboplatin-based chemotherapy, with a complete response at 67 mo. Other Authors\[[@B10],[@B13],[@B14]\] administered adjuvant chemo-therapy after surgery for adrenal secondary tumors, but provided no follow-up data.

Only one of the cases emerging from the literature review was managed with no surgery or oncological treatment. Zaidi et al\[[@B11]\] reported giving only palliative therapy to a patient with a low-stage uterine cancer and an early adrenal gland metastasis, and the outcome was very poor (she survived only 3 mo after her metastasis was diagnosed).

CONCLUSIONS
===========

Adrenal metastasis from uterine cancer is rare, but should be suspected whenever an adrenal mass is detected in the follow-up after the resection of gynecological cancer. Although the number of cases reported in the literature is very small, laparoscopic resection seems to be feasible and safe, with good oncological results.
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